CSF2 and glycogen storage disease Ib: Based on this postulate and on beneficial effects of GM-CSF therapy in glycogen storage disease type Ib, a hereditary metabolic disorder characterised by neutrophil dysfunction and intestinal inflammation, clinical trials with GM-CSF have been undertaken in CD [69,70,71].